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  The effect of NaCl plus 3% chitosan on the systolic blood 
pressure of spontaneously hypertensive rats (SHR) were 
evaluated and compared with NaCl plus KCl (NaCl, 49.36% 
+ KCl 49.36%) and chitosan or NaCl treatment alone. In 
SHR, administration of NaCl plus chitosan (44 mM Na/day) 
for two months significantly decreased the systolic blood 
pressure greater than of NaCl plus KCl and NaCl alone. NaCl 
plus chitosan resulted, though not statistically significant, in 
decreased urinary Na
+ excretion and decreased blood urea 
nitrogen levels. Urinary creatinine of NaCl plus chitosan was 
slightly decreased compared to 3 treated groups. Serum 
electrolytes  levels,  however,  remained  unchanged.  The 
combination of NaCl and chitosan may be superior to the 
conventional use of NaCl plus KCl or NaCl alone in the 
prevention of hypertension. Even though these supplementary 
diets have demonstrated potential anti-hypertensive effects 
in  the  experimental  animal  model,  further  research  is 
needed before any recommendations can be made.
Keywords: chitosan, hypertension, KCl, NaCl, spontaneously 
hypertensive rat
Introduction 
  Hypertension is one of the most common cardiovascular 
diseases and has become a worldwide problem of epidemic 
proportions, affecting 15-20% of all adults [10,11,22,26]. 
It is the most serious common chronic health problem 
because it is a significant risk factor for the development of 
arteriosclerosis, stroke, myocardial infarction, and end-stage 
renal disease [25]. Chloride ions (Cl
򰠏) may play a role in 
the development and severity of age-related hypertension 
[23]. Therefore, decreasing the dietary intake of sodium 
chloride (NaCl) is generally recommended [23,25].
    Hypertension is explained by the physiological and 
biochemical reactions of peripheral renin-angiotensin system, 
and its treatment is focused on the inhibition of angiotensin 
converting enzyme (ACE) activities for direct inhibition of 
hypertension. The naturally occurring polysaccharide, 
antihypertensive, biopolymer chitosan is an ideal candidate 
for an ACE inhibitor because it is considered to be milder 
and safer as compared with the drugs commonly used in the 
treatment of hypertension. In addition, chitosan is usually 
well-absorbed and demonstrates a multitude of other 
beneficial physiological properties [8,15].
  The naturally occurring biopolymer, chitin-chitosan, is a 
well-known food supplement that effectively lowers blood 
cholesterol concentration and controls obesity [19]. In 
addition, it has many other useful biomedical applications- 
e.g., an absorbable suture, a drug carrier, an antitumor agent, 
a hemostatic agent, and a wound-healing agent. Chitosan 
itself has been developed as a new physiologically bioactive 
material, which has been touted as a treatment for various 
disorders, including asthma, atopic dermatitis, arteriosclerosis, 
hypertension, macular degeneration, arthritis, cancer, 
diabetes, and osteoporosis, among others [8,14,15].
  This study was undertaken to examine the possible effects 
of chitosan alone and in combination with NaCl in 
spontaneously hypertensive rat (SHR) models. We also 
performed a comparative evaluation with the conventional 
use of NaCl plus KCl in an effort to find a better 
antihypertensive table salt for people to whom salt-restricted 
diets are indicated [13,17,18,27]. 
Materials and Methods
Aqueous chitosan solution 
  Chitosan was prepared by Biotech (Korea). To produce 
chitin, crab shells were ground into 180-250 mm particles 142    Sung-Hoon Park et al.
with a ball mill. The powder was then placed in 2N HCl 
solution in room temperature for 12 h. Calcium, other 
inorganic materials, and proteins were then removed with 
1 N NaOH to produce chitin. The chitin was then centrifuged 
and washed with distilled water, ethanol, and ether, in 
order, and vacuum dried at 70
oC to produce refined chitin 
in white powder form. It was then hydrolyzed with 50% 
NaOH solution at 100
oC for 5 h followed by 90% degree of 
deacetylation to produce chitosan containing 5% water and 
having a molecular weight of 100,000. A total of 52.5 g of 
flake-type chitosan was mixed with 950 g of 3% sodium 
acetate solution using a stirrer and filtered with nylon filter 
(200 mesh) to acquire a 5% chitosan solution (pH 4.5). A 
total of 324 g of natural sea salt (NaCl) containing 8% 
water, measured with a moisture meter (MA30-000v3; 
Sartorius AG, Germany), was dissolved in 1,000 ml of 
distilled water, followed by the addition of 180 ml of 5% 
chitosan solution. The resulting mixture was heated at 
90
oC for required concentration by evaporation of water.
Animals and diets 
  In vivo experiments were performed following the 
guidelines for the care and use of laboratory animals 
approved by Seoul National University [Approval No. 
SNU-070119-1]. Twenty-five SHR, 6 weeks of age and 
weighing 280-310 g (male) were purchased from Central 
Laboratory Animal, Korea. Animals were maintained in a 
certified animal house under supervision and standard 
conditions of 22 ± 2
oC and 55 ± 10% relative humidity with 
a photoperiod of 12 : 12 h of light : darkness. Water and a 
dry pellet diet (Purina Rodent Laboratory Chow; Ralston 
Purina, USA) were given ad libitum. The rats were 
acclimatized for 4 days prior to the start of the experiments 
and randomly allocated to five groups. Group 1: NaCl + 
KCl (49.36% NaCl plus 49.36% KCl), group 2: NaCl + 
chitosan (NaCl plus 3% chitosan), group 3: NaCl, group 4: 
chitosan (3%) administered orally using a metal gastric 
zonde, and group 5; untreated control. The concentration 
of sodium given was 44 mM (1 g of sodium) / day [3]. 
  After two months of consuming their respective diets, all 
rats were anaesthetized by an intramuscular injection of 
ketamine (100 mg/kg) and xylazine (10 mg/kg) into the 
right quadriceps femoris muscle. Blood and urine were 
collected from the heart and urinary bladder, respectively, 
followed by cervical dislocation. 
Body weight and systolic blood pressure 
  The body weights of the rats were measured once per week 
at the same time during the day. Measurement of the systolic 
blood pressure was performed once per week at the same 
time during the day. After the stabilization of the animals in 
a warm box at 37
oC for 15 min, the tail systolic blood 
pressure was measured with a non-invasive blood pressure 
system (ML125/R; AD Instruments Power Lab System, 
USA) and was reported as the mean value of three 
consecutive measurements [28].
Blood and urine chemistry
  Blood was centrifuged at 3,000 g for 15 min to obtain 
serum. After serum separation, we measured the levels of 
electrolytes [sodium (Na
+), chlorine (Cl
򰠏) and potassium 
(K
+)] by an electrolyte measurement apparatus based on an 
ion electrode method. Angiotensin I and II were measured 
with a rat angiotensin I and II EIA kits (Phoenix 
Pharmaceuticals, USA) according to the manufacturer’s 
instructions. 
  Urine was assayed for creatinine by a refractometer (Atago, 
Japan), blood urea nitrogen (BUN) by a commercial kit 
(BUN Kainos; Kainos, Japan) according to a modified 
urease-indole-phenol method and electrolytes (Na
+, Cl
򰠏 
and K
+) by an electrolyte measurement apparatus based on 
an ion electrode method [6].
Histopathology
  The autopsied heart and kidneys from five rats in each 
dietary group of SHR were fixed in 10% formalin buffer 
for 48 h, followed by dehydration in an alcohol-xylene 
series prior to embedding in paraffin wax. The glomerular, 
vascular, tubular, and interstitial changes were graded from 
0 to 3 observing H&E stained slides (0 = normal; 0.5 = 
minimal; 1 = slight; 2 = moderate and 3 = severe) [1].
Statistical data
  Statistical analysis was performed using Duncan’s multiple 
range test (Version 8.2; SAS Institute, USA). A p-values ＜ 
0.05 were considered statistically significant.
Results
Survival, Body weight and Systolic blood pressure 
  None of the animals died. All groups had an increase in 
body weight during the experimental period. At the end of 
the experiment, the control group gained 74.34 ± 10.91 g 
from baseline, while the chitosan, chitosan plus NaCl, and 
KCl plus NaCl treated groups increased by 77.67 ± 8.70 g, 
74.16 ±10.40 g, and 61.53 ± 14.70 g, respectively. Throughout 
the experimental period, no statistically significant difference 
in body weight changes was observed between all treated 
groups and control group (Fig. 1). The food intake was 
essentially proportional to its change in weight (data not 
shown).
  A continuous increase (control: 195.60 ± 7.90 to 215.50 ± 
5.20 mmHg) in the systolic blood pressure (SBP) was seen 
in all the groups during the experimental period. In general, 
SBP of the NaCl plus chitosan-treated group was lower 
than that of the KCl plus NaCl-treated group (232.50 ± 
7.60 mmHg) and the NaCl-treated group and higher than 
that of the chitosan-treated group (212.40 ± 5.70 mmHg) NaCl plus chitosan prevent hypertension in SHR    143
Fig. 1. Changes in body weight of spontaneously hypertensive 
rats administered dietary salts over the experimental period. 
Vertical bars represent the mean ± SD (n = 5).
Fig. 2. Changes in systolic blood pressure of spontaneously hyper-
tensive rats administered various combinations of dietary salts. 
Means with the same alphabetical letter are not significantly di-
fferent (p ＜ 0.05). Vertical bars represent the mean ± SD (n = 5).
Fig. 3. Effect of dietary salts on serum angiotensin 1 and 2 concentrations (3A and 3B). Vertical bars represent the mean ± SD (n = 5).
and control group. There was a significant decrease (p ＜ 
0.05) in SBP in the pure NaCl plus chitosan group at 2 
week only when compared to the KCl plus NaCl treated 
group, but not at 8th week (Fig. 2).
Blood and urine chemistry
  Angiotensin I and II concentration, NaCl plus chitosan 
diet showed 4.71 ± 1.50 ng/ml which was 4.89% higher 
angiotensin I than control diet (4.49 ± 0.88 ng/ml). KCl 
plus NaCl diet showed 10.46% less angiotensin I than the 
control. Angiotensin II of NaCl plus chitosan and KCl plus 
NaCl was decreased to 2.44% and 0. 85%, respectively, 
compared to the control group. No consistent differences in 
final serum angiotensin I and II were seen among the five 
groups (Fig. 3).
  In this study, serum electrolytes were similar and unchanged 
in all groups (Fig. 4). In general, sodium levels were the 
highest followed by chlorine and potassium. Na
+, K
+ and 
Cl
򰠏 levels in the urine did not differ significantly between 
the control and the test groups regardless of treatments, but 
there was a tendency toward an decrease in urinary Na
+ 
excretion when treated with NaCl plus chitosan compared 
to NaCl + KCl or NaCl alone group (Fig. 5). 
  The NaCl plus chitosan treated group had decreased BUN 
levels compared to NaCl + KCl or NaCl alone groups, though 
none of these were statistically significant (p ＜ 0.05).
  BUN levels were the lowest (2564.00 ± 454.37 mg/ dl) in 
the NaCl plus chitosan treated group and highest (3006.00 
± 1236.82 mg/dl) in the control group, followed by the 
NaCl plus KCl groups (2838.80 ± 858.77 mg/dl) (Fig. 6A). 
    Levels of urinary creatinine (Fig. 6B) significantly 
decreased in all four treated groups compared to the control 
(133.96 ± 51.37 mg/dl). The creatinine was lowest in the 
NaCl plus chitosan group (80.06 ± 22.98 mg/dl); therefore, 
the proximal tubules were thought to be less disturbed in 
the rats exposed to daily levels of NaCl plus chitosan over 144    Sung-Hoon Park et al.
Fig. 6. Influence of different diets on urine blood urea nitrogen and creatinine levels in spontaneously hypertensive rats. Means with the
different alphabetical letter are significantly different (p ＜ 0.05) compared with the control group.
Fig. 4. Effect of dietary salts on serum electrolytes (Na
+, K
+ and
Cl
򰠏). Vertical bars represent the mean ± SD (n = 5).
Fig. 5. Effect of dietary salts on urine electrolytes (Na
+, K
+ and Cl
򰠏).
Vertical bars represent the mean ± SD (n = 5).
a period of 8 weeks.
  Levels of urinary creatinine (Fig. 6B) significantly decreased 
in all four treated groups compared to the control (133.96 
± 51.37 mg/dl) (p ＜ 0.05). The creatinine was lowest in the 
NaCl plus chitosan group (80.06 ± 22.98 mg/ dl); therefore, 
the proximal tubules were thought to be less disturbed in 
the rats exposed to daily levels of NaCl plus chitosan over 
a period of 8 weeks.
Histopathological findings
    As expected, SHR of all experimental groups were 
hypertensive, but there were no histopathological signs in 
tissue properties (data not shown).
Discussion
  Hypertension is a major risk factor for cardiovascular 
diseases such as heart failure, stroke, coronary artery disease, 
and myocardial infarction [12]. It is called the ‘silent killer’ 
for good reason: Almost one-third of individuals with 
hypertension do not know that they have it and almost 50% 
of those who do know they have hypertension do not control 
it properly. Hypertension is the primary or a contributing 
cause of death in over 200,000 patients per year in the 
United States alone [20]. Therefore, there is an urgent need 
for significant research to develop new medicine to treat 
hypertension. There are a great number of pharmaceuticals 
that have been proven to be effective in lowering blood 
pressure, but usually have side effects [5]. Diet and lifestyle 
modification may also be effective tools for the prevention 
of hypertension, which could decrease the need for 
antihypertensive drugs [2]. 
  The link between sodium intake and hypertension remains 
controversial due to inconsistencies between early 
epidemiologic studies, which showed a strong positive 
relationship between salt intake, blood pressure, and the 
incidence of hypertension, and more recent studies, which 
showed only modest decreases in blood pressure with sodium 
reduction, particularly in the normotensive population [3]. 
Chrysant et al. [3] reported an increased risk of heart attacks NaCl plus chitosan prevent hypertension in SHR    145
and cardiovascular mortality in persons who appeared to 
have restricted their sodium intake, suggesting that sodium 
reduction may be harmful under some circumstances. In 
this respect, the search for diet- related preventive measures 
against hypertension is obviously of interest and within the 
scope of functional foods. 
  In the present study, we compared the consumption of an 
effective amount of NaCl plus KCl, NaCl, NaCl plus 
chitosan, and chitosan by SHRs in an effort to find a 
suitable agent for salting food that has saltiness of NaCl, 
but with antihypertensive effects. We were particularly 
interested in the SHR rats because they represent an animal 
model of the genetic predisposition to develop arterial 
hypertension during aging, and they have numerous 
similarities to humans with essential hypertension [2,21]. 
  This study showed that body weight increased progressively 
with aging and in all groups to a similar extent. The control 
SHR gained more weight than the other groups, and after 
week 8, the body weight tended to be lower in the NaCl 
plus chitosan group than that in the chitosan alone group, 
but not to a significant extent. NaCl plus 3% chitosan 
tended to reduce the blood pressure in SHRs with greater 
efficacy than NaCl plus KCl and NaCl alone. 
  Urinary electrolyte concentrations of Cl
򰠏 increased only 
when KCl was supplemented with NaCl and the level of 
Na
+, K
+ and Cl
򰠏 was lower when SHRs were treated with 
NaCl plus chitosan compared to NaCl alone. The serum 
electrolyte concentrations of Na
+ and K
+ were identical 
across all groups. On the other hand, the BUN levels of the 
NaCl plus chitosan-treated groups were lower than that of 
the control group. This finding on the BUN level suggested 
a decrease in glomerular filtration which may be explained 
by the decrease of blood pressure due to the increase of 
angiotensin I or the decrease of angiotensin II production 
[7,9,16,24]. Since urea is a final product in protein 
metabolism and is excreted in the urine via the kidney, the 
BUN level is important in the evaluation of renal function. 
Although urinary creatinine unexpectedly increased in 
control group, it was the lowest in the NaCl plus chitosan 
group. This finding indicates that the anti-hypertensive 
effect of NaCl plus chitosan may be due to the amelioration 
of kidney function in the experimental animal models. This 
combination may be a better option for dietary 
supplementation than the conventional uses of NaCl plus 
KCl or NaCl alone. 
  This study concluded that the consumption of NaCl plus 
chitosan - based functional dietary salt should be encouraged 
as part of an overall lifestyle medicine approach for the 
prevention of hypertension. To our knowledge, this is the 
first report showing the antihypertensive effect of a 
composition of NaCl plus chitosan. This composition may 
be applied as a substitute table salt for imparting saltiness 
to dishes or as an ingredient in crackers, snack foods, and 
other food products requiring salt, which would be 
particularly appropriate for patients recommended to 
decrease the amount of salt in their diet. As there are 
several limitations in this study, further research is needed 
to identify bioactive compound(s) and the anti-hypertensive 
mechanism(s) of action of NaCl plus chitosan. 
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